Market Access and Reimbursement
We are health economics consultants who provide end-to-end market access and reimbursement advisory services to support funding across PBS, MBS and Prescribed List pathways.
Connect With An Access Strategist →Supporting reimbursement decisions in complex HTA environments
This service supports decisions about reimbursement pathways, evidence positioning, pricing strategy and timing of market entry across PBS, MBS and Prescribed List pathways.
These decisions are typically made under conditions of uncertainty, evolving HTA standards and committee judgement — so how evidence is framed and interpreted can be as important as the evidence itself.
Select a pathway below to explore our detailed FAQs and navigate the Australian HTA landscape with confidence:
PBAC Submission FAQs
MSAC Submission FAQs
Prescribed List FAQs
Explore detailed HTA submission pathways
PBAC Submission FAQs
Navigate PBS reimbursement requirements, comparator selection, economic evaluation and PBAC committee expectations.
MSAC Submission FAQs
Understand MBS funding pathways, evidence standards, clinical utility and MSAC evaluation frameworks.
Prescribed List FAQs
Strategic guidance for medical device reimbursement, benefit categories and private payer positioning.
Decision-ready reimbursement strategy and advisory
Pulse Economics helps pharmaceutical, biotech, medtech and diagnostics sponsors navigate market access and reimbursement pathways with clarity and realism.
Our advice is shaped by first-hand PBAC and MSAC submission evaluation experience, meaning we understand not only what is required, but how submissions are assessed in practice.
We work with clients to anticipate committee concerns, clarify trade-offs, and design strategies that are robust to evaluation and policy scrutiny.
Market access support in practice
PBAC, MSAC and Prescribed List pathway strategy
Strategic reimbursement pathway assessment aligned to funding and HTA objectives.
Comparator, endpoint and PICO strategy
Decision-focused evidence positioning designed for HTA evaluation scrutiny.
Submission drafting and review
Submission design, drafting, critique and response to evaluation issues.
Reimbursement and payer positioning
Positioning strategies across public and private reimbursement environments.
Pre-submission and post-decision support
Strategic advisory across all phases of the reimbursement lifecycle.
Tailored evidence interpretation
All deliverables are adapted to the product maturity and evidence base.
Built for real-world committee decision-making
Evaluator-informed
Grounded in experience assessing PBAC and MSAC submissions.
Decision-focused
Built for committee deliberation, not just technical compliance.
Integrated
Linking clinical evidence, economic modelling and policy context.
Pragmatic
Recognising uncertainty, constraints and real-world HTA trade-offs.
Relevant across the full product lifecycle
Early Development and Pathway Planning
Pre-submission Strategy and Evidence Positioning
Initial and Resubmission Support
Post-decision Strategy and Lifecycle Management
Independent advice grounded in real HTA evaluation
Direct PBAC and MSAC evaluation experience
First-hand insight into how committees assess evidence and submissions.
Deep HTA and reimbursement understanding
Expertise across Australian reimbursement, policy and committee processes.
Strong evidence and modelling integration
Linking evidence strategy, modelling and reimbursement positioning.
Clear and defensible strategic advice
Grounded in how real-world committee decisions are actually made.
Explore how we can support your market access pathway
Strategic reimbursement outcomes begin with evidence, positioning and decision frameworks designed for real HTA scrutiny.
Connect With An Access Strategist →